A new EU approach to cancer screening
September 22, 2022 – Abstract Dr. C.Bour https://ec.europa.eu/commission/presscorner/detail/fr/QANDA_22_5584 Within the framework of the European program...
Liquid biopsies, the Grail?
Synthesis Dr. C.Bour, September 15, 2022 Main article Article by Brenna Miller The Damocles syndrome...
The risks of screening: an elephant in the room
This article proposes a synthesis of two points of view of Dutch academics written for...
Potential benefits, as well as harms, from the COVID-19 disruption on cancer screening
May, 28th Online early publication https://doi.org/10.17061/phrp32122208https://www.phrp.com.au/wp-content/uploads/2022/04/PHRP32122208.pdf During the Covid pandemic, some scientists and journalists from various...
Update on Tomosynthesis
May 17, 2022 Article in Auntminnie Reminder: Tomosynthesis (or 3D mammography) is a radiological imaging...
When marketing, finance, lobbying, and advertising invite themselves into the health care sector
Commercial determinants of cancer control policy (Eurohealth) https://eurohealthobservatory.who.int/publications/i/commercial-determinants-of-cancer-control-policy-(eurohealth)European Observatory on Health Systems and Policies (downloadable)...
Cancer Screening—The Good, the Bad, and the Ugly
JAMA Surg. Published online April 6, 2022. doi:10.1001/jamasurg.2022.0669https://jamanetwork.com/journals/jamasurgery/article-abstract/2790973 H. GilbertWelch,MD, MPH-Center for Surgery and Public Health,...
Dual-energy angiomammography
November 27, C.Bour MD Angiomammography is a recent technology that is not useful for screening...
October, the cruelest month?
Summary Dr. Cécile Bour, November 15, 2021 About an article published on October 15 in...